Tp53 and its potential therapeutic role as a target in bladder cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin. Eur Urol. 2016;69:60–69.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Catto JW, Goebell PJ, et al. Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urol Oncol. 2014;32:1078–1087.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Van Der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64:1911–1914.
   PubMed Web of Science ®Google Scholar
• van der Kwast TH, Bapat B. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. Curr Opin Urol. 2009;19:516–521.
   PubMed Web of Science ®Google Scholar
• Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol. 2009;1:a001883.
   PubMed Web of Science ®Google Scholar
• Poyurovsky MV, Katz C, Laptenko O, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010;17:982–989.
   PubMed Web of Science ®Google Scholar
• Li M, Brooks CL, Wu-Baer F, et al. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003;302:1972–1975.
   PubMed Web of Science ®Google Scholar
• Muller L, Schaupp A, Walerych D, et al. Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J Biol Chem. 2004;279:48846–48854.
   PubMed Web of Science ®Google Scholar
• Walerych D, Kudla G, Gutkowska M, et al. Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem. 2004;279:48836–48845.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Canman CE, Taya Y, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997;11:3471–3481.
   PubMed Web of Science ®Google Scholar
• Meek DW. Mechanisms of switching on p53: a role for covalent modification? Oncogene. 1999;18:7666–7675.
   PubMed Web of Science ®Google Scholar
• Wu X, Shell SM, Yang Z, et al. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation. Cancer Res. 2006;66:2997–3005.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10:94–99.
   PubMed Web of Science ®Google Scholar
• Weber JD, Jeffers JR, Rehg JE, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000;14:2358–2365.
   PubMed Web of Science ®Google Scholar
• Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell. 1998;92:713–723.
   PubMed Web of Science ®Google Scholar
• Mayo LD, Dixon JE, Durden DL, et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002;277:5484–5489.
   PubMed Web of Science ®Google Scholar
• Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269–1283.
   PubMed Web of Science ®Google Scholar
• Flores ER, Lozano G. The p53 family grows old. Genes Dev. 2012;26:1997–2000.
   PubMed Web of Science ®Google Scholar
• Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415:45–53.
   PubMed Web of Science ®Google Scholar
• Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14:518–528.
   PubMed Web of Science ®Google Scholar
• Chan TA, Hermeking H, Lengauer C, et al. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616–620.
   PubMed Web of Science ®Google Scholar
• Utrera R, Collavin L, Lazarevic D, et al. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. Embo J. 1998;17:5015–5025.
   PubMed Web of Science ®Google Scholar
• Carrier F, Georgel PT, Pourquier P, et al. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol. 1999;19:1673–1685.
   PubMed Web of Science ®Google Scholar
• Ohki R, Nemoto J, Murasawa H, et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem. 2000;275:22627–22630.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–299.
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053–1058.
   PubMed Web of Science ®Google Scholar
• Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis. 2005;26:1317–1322.
   PubMed Web of Science ®Google Scholar
• Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995;377:646–649.
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683–694.
   PubMed Web of Science ®Google Scholar
• Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440–450.
   PubMed Web of Science ®Google Scholar
• Zhang G, Park MA, Mitchell C, et al. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem. 2016;291:20823.
   PubMed Web of Science ®Google Scholar
• Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet. 2000;26:122–127.
   PubMed Web of Science ®Google Scholar
• Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582–1584.
   PubMed Web of Science ®Google Scholar
• Teodoro JG, Parker AE, Zhu X, et al. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science. 2006;313:968–971.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995;55:6161–6165.
   PubMed Web of Science ®Google Scholar
• Iotsova V, Stehelin D. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ. 1996;7:629–634.
   PubMedGoogle Scholar
• Sun Y, Wenger L, Rutter JL, et al. p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem. 1999;274:11535–11540.
   PubMed Web of Science ®Google Scholar
• Gadea G, Roger L, Anguille C, et al. TNFalpha induces sequential activation of Cdc42- and p38/p53-dependent pathways that antagonistically regulate filopodia formation. J Cell Sci. 2004;117:6355–6364.
   PubMed Web of Science ®Google Scholar
• Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53? Biol Cell. 2006;98:141–152.
   PubMed Web of Science ®Google Scholar
• Wahl GM, Linke SP, Paulson TG, et al. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv. 1997;29:183–219.
   PubMedGoogle Scholar
• Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res. 2002;511:45–62.
   PubMed Web of Science ®Google Scholar
• Mummenbrauer T, Janus F, Muller B, et al. p53 Protein exhibits 3ʹ-to-5ʹ exonuclease activity. Cell. 1996;85:1089–1099.
   PubMed Web of Science ®Google Scholar
• Dong C, Zhang F, Luo Y, et al. p53 suppresses hyper-recombination by modulating BRCA1 function. DNA Repair (Amst). 2015;33:60–69.
   PubMed Web of Science ®Google Scholar
• Moureau S, Luessing J, Harte EC, et al. A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining. Open Biol. 2016;6:160225.
   PubMed Web of Science ®Google Scholar
• Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 1994;266:1376–1380.
   PubMed Web of Science ®Google Scholar
• Smith ML, Zhan Q, Bae I, et al. Role of retinoblastoma gene product in p53-mediated DNA damage response. Exp Cell Res. 1994;215:386–389.
   PubMed Web of Science ®Google Scholar
• Wylie A, Jones AE, Abrams JM. p53 in the game of transposons. Bioessays. 2016;38:1111–1116.
   PubMed Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49–53..
   PubMed Web of Science ®Google Scholar
• Ferraiuolo M, di Agostino S, Blandino G, et al. Oncogenic Intra-p53 family member interactions in human cancers. Front Oncol. 2016;6:77.
   PubMed Web of Science ®Google Scholar
• Papadogianni D, Soulitzis N, Delakas D, et al. Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence. Tumour Biol. 2014;35:2481–2489.
   PubMed Web of Science ®Google Scholar
• Karni-Schmidt O, Castillo-Martin M, Shen TH, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol. 2011;178:1350–1360.
   PubMed Web of Science ®Google Scholar
• Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346–355.
   PubMed Web of Science ®Google Scholar
• Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;8:531–539.
   PubMed Web of Science ®Google Scholar
• Gao JP, Uchida T, Wang C, et al. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol. 2000;16:469–475.
   PubMed Web of Science ®Google Scholar
• Erill N, Colomer A, Verdu M, et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol. 2004;13:217–223.
   PubMedGoogle Scholar
• Shariat SF, Bolenz C, Karakiewicz PI, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105:489–495..
   PubMed Web of Science ®Google Scholar
• George B, Datar RH, Wu L, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007;25:5352–5358.
   PubMed Web of Science ®Google Scholar
• Abdel-Fattah R, Challen C, Griffiths TR, et al. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer. 1998;77:2230–2238.
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678–686.
   PubMed Web of Science ®Google Scholar
• Schmitz-Drager BJ, Goebell PJ, Ebert T, et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol. 2000;38:691–699. discussion 700.
   PubMed Web of Science ®Google Scholar
• Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006;24:5552–5564.
   PubMed Web of Science ®Google Scholar
• Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res. 2003;9:235–242.
   PubMed Web of Science ®Google Scholar
• Kawamoto K, Enokida H, Gotanda T, et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun. 2006;339:790–796.
   PubMed Web of Science ®Google Scholar
• Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994;86:1325–1330.
   PubMed Web of Science ®Google Scholar
• Schmitz-Drager BJ, Kushima M, Goebell P, et al. p53 and MDM2 in the development and progression of bladder cancer. Eur Urol. 1997;32:487–493.
   PubMed Web of Science ®Google Scholar
• Maluf FC, Cordon-Cardo C, Verbel DA, et al. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol. 2006;17:1677–1686.
   PubMed Web of Science ®Google Scholar
• Nag S, Zhang X, Srivenugopal KS, et al. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21:553–574.
   PubMed Web of Science ®Google Scholar
• Abat D, Demirhan O, Inandiklioglu N, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett. 2014;8:25–32.
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Seth Lerner S, Kwiatkowski DJ. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507:315–322.
   PubMed Web of Science ®Google Scholar
• Al-Ahmadie HA, Iyer G, Lee BH, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48:356–358.
   PubMed Web of Science ®Google Scholar
• Nordentoft I, Lamy P, Birkenkamp-Demtroder K, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014;7:1649–1663.
   PubMed Web of Science ®Google Scholar
• Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45:1459–1463.
   PubMed Web of Science ®Google Scholar
• Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70:3463–3472.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2014;27:271–280.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Khaira D, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016;122:702–711.
   PubMed Web of Science ®Google Scholar
• Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377–3386.
   PubMed Web of Science ®Google Scholar
• Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999;18:477–485.
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Strano S, Emiliozzi V, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 2006;10:191–202.
   PubMed Web of Science ®Google Scholar
• Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv Cancer Res. 2007;97:1–23.
   PubMed Web of Science ®Google Scholar
• Fontemaggi G, Dell’Orso S, Trisciuoglio D, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 2009;16:1086–1093.
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268–1286.
   PubMed Web of Science ®Google Scholar
• Valenti F, Ganci F, Fontemaggi G, et al. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget. 2015;6:5547–5566.
   PubMed Web of Science ®Google Scholar
• He C, Li L, Guan X, et al. Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 2016;62:43–53.
   PubMed Web of Science ®Google Scholar
• Oren M, Tal P, Rotter V. Targeting mutant p53 for cancer therapy. Aging (Albany NY). 2016;8:1159–1160.
   PubMedGoogle Scholar
• Walerych D, Lisek K, Sommaggio R, et al. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol. 2016;18:897–909.
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264.
   PubMed Web of Science ®Google Scholar
• Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer. 1993;53:365–370.
   PubMed Web of Science ®Google Scholar
• Sarkis A, Zhang Z, Cordoncardo C, et al. P53 nuclear overexpression and disease progression in ta-bladder carcinoma. Int J Oncol. 1993;3:355–360.
   PubMed Web of Science ®Google Scholar
• Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784–788.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004;45:606–612.
   PubMed Web of Science ®Google Scholar
• Serth J, Kuczyk MA, Bokemeyer C, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer. 1995;71:201–205.
   PubMed Web of Science ®Google Scholar
• Gil P, Allepuz C, Blas M, et al. Significance of protein p53 overexpression in the clinical course of high-risk superficial bladder cancer. Urol Int. 2003;70:172–177.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Parekh DJ, Ben-Porat L, et al. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007;99:281–285.
   PubMed Web of Science ®Google Scholar
• Lopez-Knowles E, Hernandez S, Kogevinas M, et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res. 2006;12:6029–6036.
   PubMed Web of Science ®Google Scholar
• Saint F, Le Frere Belda MA, Quintela R, et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG). Eur Urol. 2004;45:475–482.
   PubMed Web of Science ®Google Scholar
• Park J, Song C, Shin E, et al. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2013;31:849–856.
   PubMed Web of Science ®Google Scholar
• Peyromaure M, Weibing S, Sebe P, et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology. 2002;59:409–413.
   PubMed Web of Science ®Google Scholar
• Du J, Wang SH, Yang Q, et al. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol. 2016;14:137.
   PubMed Web of Science ®Google Scholar
• Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252:706–709.
   PubMed Web of Science ®Google Scholar
• Esrig D, Spruck CH 3rd, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389–1397.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014–1024.
   PubMed Web of Science ®Google Scholar
• Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol. 2004;22:112–118.
   PubMed Web of Science ®Google Scholar
• Frank I, Cheville JC, Blute ML, et al. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer. 2004;101:1803–1808.
   PubMed Web of Science ®Google Scholar
• Fleshner N, Kapusta L, Ezer D, et al. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol. 2000;164:1177–1182.
   PubMed Web of Science ®Google Scholar
• Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol. 1999;10:1011–1021.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13:1384–1390.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29:3443–3449.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165.
   PubMed Web of Science ®Google Scholar
• Selivanova G, Ryabchenko L, Jansson E, et al. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol. 1999;19:3395–3402.
   PubMed Web of Science ®Google Scholar
• Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med. 1997;3:632–638.
   PubMed Web of Science ®Google Scholar
• Protopopova M, Selivanova G. Inhibition of p53 activity in vitro and in living cells by a synthetic peptide derived from its core domain. Cell Cycle. 2003;2:592–595.
   PubMed Web of Science ®Google Scholar
• Hsieh JT, Zhou J, Gore C, et al. R11, a novel cell-permeable peptide, as an intravesical delivery vehicle. BJU Int. 2011;108:1666–1671.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu K, Ding C, et al. Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus. Oncotarget. 2015;6:37782–37791.
   PubMed Web of Science ®Google Scholar
• Takimoto R, Wang W, Dicker DT, et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther. 2002;1:47–55.
   PubMed Web of Science ®Google Scholar
• Madka V, Mohammed A, Li Q, et al. TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma. Am J Cancer Res. 2015;5:3030–3041.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kwiatkowski DJ. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther. 2015;14:174–182.
   PubMed Web of Science ®Google Scholar
• Synnott NC, Murray A, McGowan PM, et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?. Int J Cancer. 2016. doi:10.1002/ijc.30425.
   PubMed Web of Science ®Google Scholar